|4.51|| +0.17 / +3.92%|
Fibrocell Science, Inc. develops autologous cellular system. It a commercial-stage, autologous cellular therapeutic company focused on the development of products for aesthetic, medical and scientific applications. The company has a pipeline of therapeutic and aesthetic product development programs based on the first Food and Drug Administration approved cell-based product, LAVIV™ (azficel-T), in aesthetics, all of which are based on the autologous fibroblast cell. Its clinical and pre-clinical programs include treatments for restrictive burn scars, vocal cord scars, and acne scars. Fibrocell Science was founded on September 1, 2009 and is headquartered in Exton, PA.
|David M. Pernock||Chairman, President & Chief Executive Officer|
|Keith Alan Goldan||CFO, Secretary, Treasurer & Senior Vice President|
|John Maslowski||Vice President-Scientific Affairs|
|Laura Campbell||Vice President-Planning|
|Robert James Sheroff||Vice President-Technical Operations|